Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
BCDA logo BCDA
Upturn stock ratingUpturn stock rating
BCDA logo

Biocardia Inc (BCDA)

Upturn stock ratingUpturn stock rating
$2.15
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/27/2025: BCDA (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $6

1 Year Target Price $6

Analysts Price Target For last 52 week
$6Target price
Low$1.62
Current$2.15
high$4.66

Analysis of Past Performance

Type Stock
Historic Profit -84.69%
Avg. Invested days 18
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/27/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 11.13M USD
Price to earnings Ratio -
1Y Target Price 6
Price to earnings Ratio -
1Y Target Price 6
Volume (30-day avg) 1
Beta 0.84
52 Weeks Range 1.62 - 4.66
Updated Date 06/30/2025
52 Weeks Range 1.62 - 4.66
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -2.14

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -281733.35%

Management Effectiveness

Return on Assets (TTM) -218.06%
Return on Equity (TTM) -737.89%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 10929905
Price to Sales(TTM) 3710.82
Enterprise Value 10929905
Price to Sales(TTM) 3710.82
Enterprise Value to Revenue 3643.3
Enterprise Value to EBITDA -3.16
Shares Outstanding 5177890
Shares Floating 3886990
Shares Outstanding 5177890
Shares Floating 3886990
Percent Insiders 21.66
Percent Institutions 4.75

Analyst Ratings

Rating 1
Target Price 6
Buy -
Strong Buy 1
Buy -
Strong Buy 1
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Biocardia Inc

stock logo

Company Overview

overview logo History and Background

BioCardia, Inc. was founded in 1998 and is focused on developing novel therapeutics for cardiovascular diseases. It has evolved from research into clinical-stage development, focusing on cell-based therapies.

business area logo Core Business Areas

  • CardiAMP Cell Therapy System: BioCardia's lead program, CardiAMP, uses a patient's own bone marrow cells to treat heart failure and chronic myocardial ischemia. It involves a diagnostic test to identify patients likely to respond to the therapy.
  • AVANCE Clinical Trial: The AVANCE trial is evaluating the efficacy of CardiAMP cell therapy in patients with ischemic heart failure.

leadership logo Leadership and Structure

The leadership team includes Peter Altman (President & CEO). The organizational structure is typical for a publicly traded biotech company, with departments focused on research, clinical development, manufacturing, and commercialization.

Top Products and Market Share

overview logo Key Offerings

  • CardiAMP Cell Therapy System: This is BioCardia's primary product under development. It is a cell-based therapy for heart disease, utilizing a patient's own cells to regenerate heart tissue. Currently in clinical trials (AVANCE). Market share is pending FDA approval. Competitors include companies developing similar regenerative therapies, though direct competitors with the exact CardiAMP approach are not widely specified.

Market Dynamics

industry overview logo Industry Overview

The regenerative medicine industry is growing, with increasing investment in cell-based therapies for various diseases. Cardiovascular disease remains a significant global health challenge, creating a substantial market opportunity.

Positioning

BioCardia is positioned as a clinical-stage company focused on cell therapies for heart disease. Its competitive advantage lies in its proprietary CardiAMP system and diagnostic approach.

Total Addressable Market (TAM)

The TAM for heart failure therapies is estimated to be in the billions of dollars annually. BioCardia is targeting a segment of this market with its personalized cell therapy approach.

Upturn SWOT Analysis

Strengths

  • Proprietary CardiAMP technology
  • Personalized cell therapy approach
  • Clinical-stage development
  • Focus on unmet medical needs in cardiovascular disease

Weaknesses

  • Reliance on clinical trial success
  • High cash burn rate
  • Limited commercial revenue
  • Susceptibility to regulatory hurdles

Opportunities

  • Positive clinical trial results
  • Partnerships with larger pharmaceutical companies
  • Expansion into new indications
  • FDA approval and commercial launch

Threats

  • Clinical trial failures
  • Regulatory delays
  • Competition from alternative therapies
  • Market adoption challenges

Competitors and Market Share

competitor logo Key Competitors

  • MESO
  • ATHX
  • CRBP

Competitive Landscape

BioCardia faces competition from other companies developing cell and gene therapies for cardiovascular disease. Its competitive advantage lies in its personalized approach and specific technology platform.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is characterized by progress through clinical trials and research activities.

Future Projections: Future growth is contingent upon successful clinical trial outcomes and FDA approval. Analyst estimates would vary depending on these factors.

Recent Initiatives: Recent strategic initiatives include advancing the CardiAMP program through clinical trials and seeking partnerships for commercialization.

Summary

BioCardia is a clinical-stage biotech company focused on cell therapies for heart disease. Its success hinges on positive clinical trial outcomes and regulatory approval of its CardiAMP system. The company faces challenges related to funding and competition, but holds potential for growth if its therapies prove effective. Investors should be aware of the high-risk, high-reward nature of investing in a clinical-stage biotech company.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • SEC Filings (10-K, 10-Q), Company Website, Analyst Reports

Disclaimers:

This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share estimates are approximations.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Biocardia Inc

Exchange NASDAQ
Headquaters Sunnyvale, CA, United States
IPO Launch date 2008-03-14
CEO, President & Director Dr. Peter A. Altman Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 17
Full time employees 17

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths products. It has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.